Codex Vet Drug Residue Committee Discusses MRLs, Honey, JEFCA Priority List, Etc.
The Food Safety and Inspection Service reports that the Codex Committee on Residues of Veterinary Drugs in Foods (CCRVDF) held its 20th session, May 7-11, in San Juan, Puerto Rico, with 177 delegates from 47 countries, one regional organization, and 10 observer organizations. A detailed Delegate’s Report is available here. Highlights include:
Sign up for a free preview to unlock the rest of this article
Export Compliance Daily combines U.S. export control news, foreign border import regulation and policy developments into a single daily information service that reliably informs its trade professional readers about important current issues affecting their operations.
- Recommending to the Commission the adoption of maximum residues limits (MRLs) of narasin in cattle tissue; MRLs for amoxicillin in cattle, sheep and pig tissues; and the proposed draft sampling plan for residue control for aquatic animal products and derived edible products of aquatic origin.
- Holding proposed MRLs for apramycin and monepantel to allow for further evaluation by the Joint FAO/WHO Expert Committee on Food Additives (JECFA).
- Establishing a physical working group, led by Canada, to continue work on extrapolation of data for the development of MRLs.
- Continuing the electronic working groups (eWGs) to develop guidances for honey and for multi-residue analytical methods, and to develop risk management advice for veterinary drugs for which JECFA could not recommend Acceptable Daily Intake (ADI) values or MRLs due to specific human health concerns. The honey eWG will be led by the United Kingdom, and the multi-residue analytical methods eWG will be co-chaired by the United Kingdom and Canada.
- Including gentian violet, lasalocid, phenylpyrazole, emamcetin benzoate, derquantel, monepantel, and apramycin on the priority list for JECFA evaluation. The Committee was sharply divided by the proposal to include zilpaterol on the JECFA priority list, because this compound is a beta-agonist, and the EU opposes the development of MRLs for beta-agonists in general, regardless of JECFA evaluation.
- Sending to the Commission a proposal to form a new electronic Working Group (eWG) to further develop risk management advice for drugs for which JECFA could not recommend ADI and/or MRLs due to specific human health concerns.
The next session is tentatively scheduled for August 2013.